James W. Janc

1.5k total citations
51 papers, 1.1k citations indexed

About

James W. Janc is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, James W. Janc has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 13 papers in Genetics and 12 papers in Oncology. Recurrent topics in James W. Janc's work include Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers) and Protease and Inhibitor Mechanisms (8 papers). James W. Janc is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers) and Protease and Inhibitor Mechanisms (8 papers). James W. Janc collaborates with scholars based in United States, Switzerland and Australia. James W. Janc's co-authors include Kyle Elrod, P.P.A. Humphrey, Craig A. Townsend, Bret M. Benton, Mathai Mammen, Paul A. Sprengeler, Christopher S. Lunde, B.A. Katz, Petr Kuzmič and Steve Sideris and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

James W. Janc

50 papers receiving 1.1k citations

Peers

James W. Janc
Philip E.J. Sanderson United States
Daniel R. McMasters United States
Eric M. Bennett United States
Federico Falchi Italy
Nickolay Y. Chirgadze United States
Malika Kumarasiri United States
Cristina Tintori Italy
Nicola G. Wallis United Kingdom
Cecilia Pozzi Italy
V. Nienaber United States
Philip E.J. Sanderson United States
James W. Janc
Citations per year, relative to James W. Janc James W. Janc (= 1×) peers Philip E.J. Sanderson

Countries citing papers authored by James W. Janc

Since Specialization
Citations

This map shows the geographic impact of James W. Janc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Janc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Janc more than expected).

Fields of papers citing papers by James W. Janc

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. Janc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Janc. The network helps show where James W. Janc may publish in the future.

Co-authorship network of co-authors of James W. Janc

This figure shows the co-authorship network connecting the top 25 collaborators of James W. Janc. A scholar is included among the top collaborators of James W. Janc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Janc. James W. Janc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenbaum, James T., Erik Verner, William B. Jones, et al.. (2024). Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity. 1(1). 3 indexed citations
2.
Hegde, Sharath S. & James W. Janc. (2014). Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection. Expert Review of Anti-infective Therapy. 12(12). 1463–1475. 7 indexed citations
3.
Harbert, Jack L., et al.. (2013). Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. Journal of Thrombosis and Thrombolysis. 38(2). 235–240. 6 indexed citations
4.
Barriere, Steven L., et al.. (2011). Effects of telavancin on coagulation test results. International Journal of Clinical Practice. 65(7). 784–789. 13 indexed citations
5.
Shrader, William D., Aleksandr Kolesnikov, Roopa Rai, et al.. (2006). Factor VIIa inhibitors: Gaining selectivity within the trypsin family. Bioorganic & Medicinal Chemistry Letters. 16(6). 1596–1600. 12 indexed citations
6.
Young, Wendy B., Joyce Mordenti, William D. Shrader, et al.. (2006). Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model. Bioorganic & Medicinal Chemistry Letters. 16(7). 2037–2041. 24 indexed citations
7.
Lee, Chang-Sun, Weili Liu, Paul A. Sprengeler, et al.. (2006). Design of novel, potent, and selective human β-tryptase inhibitors based on α-keto-[1,2,4]-oxadiazoles. Bioorganic & Medicinal Chemistry Letters. 16(15). 4036–4040. 11 indexed citations
8.
Sprengeler, Paul A., Michael B. Shaghafi, Jeffrey R. Spencer, et al.. (2006). Discovery of novel hydroxy pyrazole based factor IXa inhibitor. Bioorganic & Medicinal Chemistry Letters. 16(10). 2796–2799. 12 indexed citations
9.
Kolesnikov, Aleksandr, Roopa Rai, Wendy B. Young, et al.. (2006). Factor VIIa inhibitors: Improved pharmacokinetic parameters. Bioorganic & Medicinal Chemistry Letters. 16(8). 2243–2246. 9 indexed citations
10.
Young, Wendy B., Paul A. Sprengeler, William D. Shrader, et al.. (2005). Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation. Bioorganic & Medicinal Chemistry Letters. 16(3). 710–713. 9 indexed citations
11.
Setti, Eduardo L., et al.. (2005). 3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity. Bioorganic & Medicinal Chemistry Letters. 15(5). 1529–1534. 25 indexed citations
12.
Katz, B.A., Christine Luong, Joseph D. Ho, et al.. (2004). Dissecting and Designing Inhibitor Selectivity Determinants at the S1 Site Using an Artificial Ala190 Protease (Ala190 uPA). Journal of Molecular Biology. 344(2). 527–547. 29 indexed citations
13.
Kuzmič, Petr, Craig Hill, & James W. Janc. (2004). Practical Robust Fit of Enzyme Inhibition Data. Methods in enzymology on CD-ROM/Methods in enzymology. 383. 366–381. 13 indexed citations
14.
Kuzmič, Petr, et al.. (2003). Kinetic determination of tight-binding impurities in enzyme inhibitors. Analytical Biochemistry. 319(2). 272–279. 4 indexed citations
15.
Katz, B.A., Kyle Elrod, Erik Verner, et al.. (2003). Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-directed Serine Protease Inhibitors. Journal of Molecular Biology. 329(1). 93–120. 30 indexed citations
16.
Sperandio, David, Anthony R. Gangloff, Joane Litvak, et al.. (2002). Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorganic & Medicinal Chemistry Letters. 12(21). 3129–3133. 29 indexed citations
17.
Katz, B.A., Paul A. Sprengeler, Christine Luong, et al.. (2001). Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chemistry & Biology. 8(11). 1107–1121. 51 indexed citations
18.
Meanwell, Nicholas A., Zhilei Qiu, Dennis Hernandez, et al.. (2001). Structure–activity relationship studies of a bisbenzimidazole-based, Zn2+-dependent inhibitor of HCV NS3 serine protease. Bioorganic & Medicinal Chemistry Letters. 11(17). 2355–2359. 34 indexed citations
19.
Katz, B.A., Kyle Elrod, Christine Luong, et al.. (2001). A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site11Edited by D. Rees. Journal of Molecular Biology. 307(5). 1451–1486. 61 indexed citations
20.
Janc, James W., Marion H. O’Leary, & W. W. Cleland. (1992). A kinetic investigation of phosphoenolpyruvate carboxylase from Zea mays. Biochemistry. 31(28). 6421–6426. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip E.J. Sanderson Breakdown of academic impact, for papers by Daniel R. McMasters Breakdown of academic impact, for papers by Eric M. Bennett Breakdown of academic impact, for papers by Federico Falchi Breakdown of academic impact, for papers by Nickolay Y. Chirgadze Breakdown of academic impact, for papers by Malika Kumarasiri Breakdown of academic impact, for papers by Cristina Tintori Breakdown of academic impact, for papers by Nicola G. Wallis Breakdown of academic impact, for papers by Cecilia Pozzi Breakdown of academic impact, for papers by V. Nienaber
Rankless by CCL
2026